BioMarin Pharmaceutical (BMRN) vs Jazz Pharmaceuticals (JAZZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Jazz Pharmaceuticals (JAZZ) has outperformed BioMarin Pharmaceutical (BMRN) over the past year, gaining 68.4% versus a gain of 0.9%. Over five years, JAZZ leads with a +64.3% price change compared with -27.3% for BMRN. Jazz Pharmaceuticals is the larger company by market cap ($14.06 billion vs $10.46 billion), about 1.3 times the size, while BioMarin Pharmaceutical is growing revenue faster (+12.9% vs +4.9%).
On valuation, BioMarin Pharmaceutical trades at a lower forward P/E (8.2x vs 8.4x for Jazz Pharmaceuticals). BioMarin Pharmaceutical converts more of its revenue into profit, with a net margin of 10.8% versus -8.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMRN | JAZZ |
|---|---|---|
| Share price | $54.05 | $216.56 |
| Market cap | $10.46B | $14.06B |
| 1-day change | -2.08% | -6.33% |
| YTD return | -7.12% | +35.99% |
| 1-year return | +0.91% | +68.36% |
| 5-year return | -27.26% | +64.31% |
| P/E ratio (TTM) | 146.08 | 14.84 |
| Forward P/E | 8.15 | 8.36 |
| EPS (TTM) | $0.37 | $14.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.22B | $4.27B |
| Revenue growth (YoY) | +12.87% | +4.88% |
| Net income (latest FY) | $348.90M | $-356.15M |
| Gross margin | 77.73% | — |
| Operating margin | 12.71% | -10.08% |
| Net margin | 10.83% | -8.35% |
| 52-week high | $70.98 | $266.38 |
| 52-week low | $49.26 | $128.80 |
| Distance from 52-week high | -23.85% | -18.70% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +69.51% | +35.99% |
| Average volume | 2.01M | 850.55K |
| Shares outstanding | 193.57M | 64.91M |
| Employees | 3,221 | 2,890 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JAZZ has outperformed BMRN by 67.4 percentage points over the past year.
- BioMarin Pharmaceutical trades at a higher earnings multiple (146.1x vs 14.8x trailing P/E).
- BioMarin Pharmaceutical is more profitable, keeping 10.8 cents of every revenue dollar as net income versus -8.3 cents for Jazz Pharmaceuticals.
- BioMarin Pharmaceutical grew revenue faster in its latest fiscal year (+12.87% vs +4.88%).
About BioMarin Pharmaceutical
BMRN stock →BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,221 employees
About Jazz Pharmaceuticals
JAZZ stock →Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,890 employees
BMRN vs JAZZ FAQ
Which is bigger, BioMarin Pharmaceutical or Jazz Pharmaceuticals?
Jazz Pharmaceuticals (JAZZ) is larger, with a market capitalization of $14.06B compared with $10.46B for BioMarin Pharmaceutical (BMRN).
Which stock has performed better over the past year, BMRN or JAZZ?
JAZZ returned +68.36% over the past 12 months, compared with +0.91% for BMRN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BMRN or JAZZ?
JAZZ has the lower trailing P/E at 14.8, versus 146.1 for BMRN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are BioMarin Pharmaceutical and Jazz Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.